These studies aim to assess the differences in efficacy when these drugs are combined with letrozole to treat HR+/HER2-/PIK3CA-mutated breast cancer patients who have developed resistance to CDK4/6 inhibitors and endocrine therapy. Here, ERBB2 is linked to breast carcinoma.